BlueRock Therapeutics described an automated system aimed at high-throughput auditing across cell therapy workflows, targeting analytical gaps created by small batch sizes and complex liquid-handling needs. The company said the system is designed to reduce sample-volume burdens and accelerate cell-therapy development and scaling. The broader manufacturing challenge is also showing up in gene therapy vector supply constraints. Researchers highlighted that AAV purification remains a bottleneck because current resins can’t effectively distinguish full from empty capsids, and harsh conditions and low flow rates add cost and time. Together, the updates reinforce that downstream analytics and upstream vector processing are now central constraints for capacity buildout, not just clinical efficacy. Companies that can standardize and automate audits, and improve purification selectivity, are positioned to compress timelines and reduce manufacturing variability.